Drug Trial Radar · NCT05824975
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
358
Planned (sponsor's estimate)
Start
May 30, 2023
Primary completion
Nov 12, 2025
Study completion Apr 24, 2027
Sponsor
- Lead sponsor
- GI Innovation, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Apr 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Soft Tissue Sarcoma (STS)
- Platinum-resistant Ovarian Cancer (PROC)
- Hepatocellular Carcinoma (HCC)
- Colorectal Cancer (CRC)
- HER2 Negative Breast Cancer
- Cutaneous Melanoma
- Renal Cell Carcinoma (RCC)
Interventions
GI-102 subcutaneous (SC)Drug
0.12 mg/kg, 0.24 mg/kg or Recommended phase 2 dose of GI-102 will be administered via SC injection Q3W up to 2 years (approximately 35 years).
GI-102Drug
Dose level will be escalated from 0.06 mg/kg to 0.45 mg/kg and Recommended phase 2 dose (or RP2D-1, RP2D+1) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
doxorubicinDrug
Doxorubicin will be administered intravenously at a dose of 75 mg/m2 on Day 3 every 3-week (21-day) cycle for up to 6 cycles.
paclitaxelDrug
Paclitaxel will be administered intravenously over 1 hour at a dose of 80 mg/m2 each time weekly as a diluted solution according to the prescribing information.
bevacizumabDrug
Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
eribulinDrug
Eribulin will be administered intravenously at a dose of over 1.4 mg/m2 over 2 to 5 minutes on Days 3 and 10 every 3-week (21-day) cycle.
trastuzumab deruxtecan (T-DXd)Drug
T-DXd will be administered initially as a 5.4 mg/kg (or 6.4 mg/kg only for gastric cancer) IV over 30 - 90 minutes every 3 weeks.
pembrolizumabDrug
pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
GI-102Drug
Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose escalation phase of Part A and B)Time frame: Study Day 1, assessed up to DLT period (3 weeks after treatment)
- Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs) (dose escalation phase of Part A and B)Time frame: Study Day 1, assessed up to approximately 24 months
- Objective Response Rate (ORR) (dose optimization phase of Part A, dose expansion phase of Part B, Part C and D)Time frame: Study Day 1, assessed up to approximately 24 months
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Scottsdale, Arizona · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
Mayo Clinic in Minnesota
Rochester, Minnesota · Recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Yonsei University Health System, Severance Hospital
Seoul, South Korea · Recruiting
Yonsei University Health System, Severance Hospital
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, Seoul, South Korea · Recruiting
St. Vincent's Hospital
Suwon, suwon, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.